Radio and PodcastRadio and PodcastLive Radio & Podcasts
MET-Amplified Lung Cancer: A New Target for XALKORI? artwork
Science & Medicine

MET-Amplified Lung Cancer: A New Target for XALKORI?

GRACEcast by Howard (Jack) West, MD

Jul 3, 201407:18Science & Medicine

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

About This Episode

MET-Amplified Lung Cancer: A New Target for XALKORI? is an episode from GRACEcast by Howard (Jack) West, MD. Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positiv...

Podcast

This episode belongs to GRACEcast.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jul 3, 2014, 07:18 long, audio available.

Questions About This Episode

What is MET-Amplified Lung Cancer: A New Target for XALKORI? about?

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

Where can I listen to MET-Amplified Lung Cancer: A New Target for XALKORI??

You can listen to MET-Amplified Lung Cancer: A New Target for XALKORI? online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is MET-Amplified Lung Cancer: A New Target for XALKORI? from?

MET-Amplified Lung Cancer: A New Target for XALKORI? is an episode from GRACEcast by Howard (Jack) West, MD.

How long is this episode?

This episode is 07:18 long.

When was this episode published?

This episode was published on Jul 3, 2014.

Can I save MET-Amplified Lung Cancer: A New Target for XALKORI? for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from GRACEcast?

Yes. This page shows related episodes from GRACEcast when more episodes are available from the podcast feed.